News

Everest Biopharma International Inc.

Latest News

Everest seeking US JV partner --Global Cannabis Opportunities  using Everest as a Canadian exporter to obtain global market share in anticipation of removal of the US federal prohibition constraint.

 

" Canada is the single largest exporter of cannabis flower and oil in the world.” as reported by Prohibition Partners.”

Very few US companies have  made a foray into global export markets using off shore Cannabis sources. Because of Canada's export reputation Everest BioPharma provides an opportunity as a Canadian exporter of premium product in the interim period before the US removes the federal prohibition allowing exports.

This is how the JV model with Everest works:

  • The US company owns the brands/trademarks for sale in the global markets to sell Everest's Canadian craft premium flower processed at its facility here in Canada (after EU-GMP certification).
  • In the interim, in anticipation of US federal legalization, the US company grows global market share, establishes brand awareness and registers it's trademarks in the global export markets.
  • The US company is paid portion of the profits of the export sales. Everest is paid its industry standard processing fees and their craft farmer members are paid for their product.
  • After US federal cannabis legalization and removal of prohibition the US company sells its US sourced product directly into the global markets using its already established market share and brands.
  • In addition to service revenues for the export markets, Everest will simultaneously earn valuable domestic market service revenues.
  • And the US JV partner can share in the profits of all service revenues with a high gross margin

Interested in creating a competitive advantage over your US competitors during the interim before US legalization?  Please contact us below for more information.

Past News / Press Releases

EBC application

Press Release

February 23, 2021

Everest BioPharma Gains Eligible Business Corporation Status allowing for 30% tax credit for BC investors. 

Press Release

EVEREST BIOPHARMA  Gains Eligible Business Corporation Status allowing for 30% tax credit for BC investors. Adding value to its COR Approval from HEALTH CANADA.

February 23, 2021

Kelowna, B.C., February 22, 2021 – Everest BioPharma International Inc. (the “Company” or “Everest BioPharma”) received, in February  2021, its notification of Eligible Business corporation (“EBC”) under the BC Venture Capital Act  allowing BC investors a 30% Tax Credit. The Company is presently completing the internal build-out of its state-of-the art cannabis extraction systems in Kelowna, BC. The first sales of live rosen and its derivatives are expected in May, 2021.

Everest is installing large capacity ice water bubble hash solventless processing equipment with ancillary rosen presses, which also allows the ability for “organic” registration, adding further value to its products. 

Nigel Boast, President and CEO of Everest BioPharma stated; “Our  registration  as an eligible business corporation “EBC” in BC (attracting a 30% tax credit) will facilitate funding required for us to fully implement our business plan which firstly focuses on tolling service fees and then the sale of our proprietary medical CBD products. Two recent standard processing license sales: Premium 5 with a similar business model ($40M), and LYF Food ($43M) indicate a high valuation for Everest.

Rob Hatch, COO of Everest BioPharma stated; “By processing from frozen, we save our tolling customers time and money because there is no requirement to trim and dry the product. There are approximately 147 standard cultivation licenses in Canada without extraction licenses.”

About Everest Bio Pharma International Inc.

Everest BioPharma is a private company that has recently received its notification of Eligible Business corporation (“EBC”) allowing BC investors a 30% Tax Credit.

Previously, Everest was granted a certificate of readiness by Health Canada allowing for the standard processing license to be expedited directly after completion of the internal build out, expected to be April 2021.

Established and run in Kelowna, British Columbia, Everest Biopharma has a highly skilled team comprising an experienced President and CEO Nigel Boast (B.Sc., LLB, MBA, PMP (retrd), COO Robert Hatch (B.Sc. (Hons), and Braden Job, (B.Sc Hons. Analytical chemistry).

Everest BioPharma is focused on the extraction business and the production and sale of value-added goods as well as the sale of its extraction services to other Canadian Cannabis Companies.

Investment information please contact:

Nigel Boast

President & CEO
Everest BioPharma International Inc.
Telephone: 778-581-4003

www.everestbiopharma.ca

Read Release